F-FDG-PET/CT imaging
Whole body PET/CT scan was performed. The mean dose of intravenous 18 F-FDG was 350MBq (range, 277.5-432.9 MBq). The scan coverage was from the top of the head to the mid-thigh. After the emission scan, low-dose CT was acquired for attenuation correction and anatomic localization of PET images. PET/CT scans started 45-60 min after 18 F-FDG injection. Emission scans of PET/CT were obtained in three-dimensional (3D) mode. The PET/CT images were evaluated in transverse, sagittal, and coronal planes and in rotating maximum-intensity projection series.
Interpretation of images
All patients were followed for at least 12 months. Two experienced double-board certified radiologist/nuclear physicians interpreted the 18 F-FDG PET/CT images on a high-resolution computer screen and reached a consensus for each scan. 18 F-FDG PET/CT images were judged to be positive if focal accumulation of the 18 F-FDG was detected outside of the areas of physiologic uptake, not just based on the standardized uptake values (SUV). True-positive result was defined as a PET/CT scan showing a focal 18 F-FDG positive lesion, which subsequently proved to be the trigger of the secondary HLH. PET/CT of a true-positive case contributed to identification of the cause of secondary HLH, whether it was infection or malignant disease. False-positive result was considered as hypermetabolic foci that could not be recognized as the potential cause of secondary HLH. Normal 18 F-FDG accumulations were considered as true negative. If a lesion (including noninfectious inflammatory, infectious, or malignancy disease) was identified during follow-up, the negative PET/CT was recognized as a false-negative result.
Statistical analysis
All statistical tests were performed using SPSS 20.0 software (IBM Corp.). Descriptive statistics were calculated as mean ± standard deviation (SD).
Results
Secondary HLH patients comprised 10 cases (22.2%) associated with infection, seven cases (15.6%) with rheumatic disease, and 28 cases (62.2%) with lymphoma. Based on histology and follow-up data, PET/CT images of 22 of 45 secondary HLH cases (48.9%) were considered as true positive. True-positive cases comprised five secondary HLH patients associated with infection, four secondary HLH cases associated with rheumatic diseases, and 13 secondary HLH cases associated with lymphoma. In true-positive cases, PET/ CT showed increased • 18 F-FDG PET/CT is helpful in identifying the possible causes and extent of secondary HLH. 18 F-FDG PET/CT can show not only the degree of HLH activity, but also the distribution of HLH in the whole body.
• 18 F-FDG PET/CT scans alone are not enough to make a correct differential diagnosis among different potential diseases. Ten secondary HLH cases associated with infection comprised four cases with Epstein-Barr virus (EBV), three cases with cytomegalovirus, three cases with human herpes virus. Five of ten secondary HLH patients associated with infection demonstrated obvious 18 F-FDG uptake on PET/CT, comprising three cases with EBV, one case with cytomegalovirus, and one case with human herpes virus. PET/CT of the remaining five secondary HLH patients associated with infection were considered as false negative.
Seven secondary HLH cases with rheumatic diseases comprised three cases with systemic lupus erythematosus (SLE), two cases with rheumatoid arthritis, and two cases with adult-onset Still disease. In this investigation, PET/CT of one secondary HLH patient associated with SLE demonstrated obvious 18 F-FDG uptake in multiple lymph nodes (Fig. 1) and enlarged spleen, which suggested active inflammation. PET/CT of one secondary HLH patient associated with adult-onset Still disease demonstrated obvious 18 F-FDG uptake in multiple organs. PET/CT of two secondary HLH patients associated with rheumatoid arthritis demonstrated obvious 18 F-FDG uptake in multiple joints, such as shoulder, hip, and wrist joints, which also suggested active inflammation of these joints.
Twenty-eight secondary HLH cases associated with lymphoma in this study comprised 14 cases with T-cell non-Hodgkin lymphoma (NHL), eight cases with large cell anaplastic lymphoma, four cases with diffuse large B-cell lymphoma, and two cases with Hodgkin lymphoma. In this investigation, PET/CT images of 15 of 28 secondary HLH cases associated with lymphoma did not show increased 18 F-FDG uptake. These 15 cases comprised seven cases associated with T-cell NHL, six cases with large cell anaplastic lymphoma, one case with diffuse large B-cell lymphoma, and one case with Hodgkin lymphoma. PET/CT of 13 of 28 secondary HLH patients with lymphoma demonstrated obvious 18 F-FDG uptake, comprising seven cases with T-cell NHL (Fig.  2) , two cases with large cell anaplastic lymphoma, three cases with diffuse large B-cell lymphoma (Fig. 3) , and one case with Hodgkin lymphoma (Table) .
Discussion
HLH is characterized by overwhelming immune activation, and hyperinflammation (10-13). Secondary HLH is associated with a variety of diseases. HLH triggered by infection is the most common cause (2, 14) . In our study, According to medical history and histopathology, the patient was diagnosed with secondary HLH associated with T-cell non-Hodgkin lymphoma. The PET (a, d, g), CT (b, e, h) , and fused (c, f, i) images showed significantly hypermetabolic lymph nodes in the axillary and bilateral cervical (small and medium arrows in a-f), axillary (large arrows in g-i), left inguinal, and retroperitoneal lymph nodes, and increased uptake of F-FDG PET/CT of the remaining five secondary HLH patients after infection can be considered as false-negative. In our study, PET/CT was considered to be true positive if abnormal imaging tracer uptake was detected as the cause of secondary HLH, regardless of it being caused by infection or malignant disease. However, 18 F-FDG PET/CT findings alone are not sufficient to make a differential diagnosis of infection versus malignant disease. Biopsy is essential to definitively distinguish malignancy from infection. Previous studies have reported EBV infection mimicking lymphoma on PET/CT. Mäkitie et al. (16) reported that the nasopharyngeal carcinoma patients with normal PET scans had low EBV viremia and were in remission, while two patients with abnormal PET results had high EBV concentrations and relapsed with distant metastasis. Based on these limited data, we speculate that the false-negative result of PET/CT in secondary HLH with virus infection might be related to low virus titer. As 18 F-FDG is a nonspecific tracer, it can accumulate in infectious or neoplastic tissues, and it is also observed in activated lymphocytes, monocytes, granulocytes. Therefore, the disadvantage of PET/CT in secondary HLH is the impossibility to differentiate among inflammation, infectious disease, and malignancy. However, in HLH patients this appears to be an advantage rather than a disadvantage as inflammation, infectious disease, and malignancy are the potential triggers of HLH. Further diagnostic examinations are needed in most HLH patients. Biopsy is essential to definitively distinguish malignancy from infection (17, 18) .
If HLH occurs in autoinflammatory or autoimmune diseases patients, it can be also called macrophage activation syndrome (MAS). The potential trigger of MAS patients includes arthritis, SLE, or other rheumatic diseases (13, 19) . In our study, 18 F-FDG PET/CT of one secondary HLH patient associated with SLE demonstrated obvious 18 F-FDG uptake in numerous lymph nodes, which suggested active inflammation. PET/CT has become one valuable ancillary method in evaluating rheumatoid arthritis. Wang et al. (20) reported that PET/CT could be applied not only to evaluate the extent of rheumatoid arthritis of the whole body, but also to evaluate the therapy response. In this study 18 F-FDG PET/ CT of two secondary HLH patients associated with rheumatoid arthritis demonstrated obvious 18 F-FDG uptake in multiple joints, such as shoulder, hip, wrist joints, suggesting active inflammation of these joints. Increased 18 F-FDG uptake in the wrist, hip, shoulder joints in rheumatoid arthritis patients has been reported previously (21) . In this paper 18 F-FDG PET/CT of one secondary HLH patient associated with adult-onset Still disease demonstrated obvious imaging tracer uptake in multiple organs, including lymph node, spleen, and bone marrow. In total, 18 F-FDG PET/CT plays an important role in the course of autoimmune diseases (22) (23) (24) (25) (26) , particularly in secondary HLH associated with autoimmune diseases.
Malignant lymphomas associated with HLH are often of T-cell origin (27) . In our study, PET/CT images of 15 of 28 secondary HLH cases associated with lymphoma did not show increased 18 F-FDG uptake. These 15 cases comprised seven cases associated with T-cell NHL, six cases with large cell anaplastic lymphoma, one case with diffuse large B-cell lymphoma, and one case with Hodgkin lymphoma. Cheson et al. (28) reported that PET is a strongly recommended application during therapy for patients with routinely 18 F-FDG avid diseases, such as Hodgkin lymphoma and diffuse large B-cell lymphoma. Karantanis et al. (29) reported PET avidity rate was 80%-100% in extranodal NK-cell lymphoma (ENKL), angioimmunoblastic T-cell lymphoma, and anaplastic large cell lymphoma.
A limitation of this study was its relative small sample size. HLH is a rare disease, and the standard diagnostic and treatment protocol does not recommend PET/CT scanning during the process of HLH. In this study, we retrospectively analyzed secondary HLH patients who underwent PET/CT scan to identify the underlying cause of HLH. Therefore, diagnostic accuracy in the current study may be influenced by referral bias or selection bias. Although the results of this study are still preliminary, the data suggest that PET/ CT may be effective in diagnosing and aiding diagnoses in patients with secondary HLH.
In conclusion, this clinical research suggests that PET/CT is helpful for identifying the possible trigger and extent of secondary HLH. PET/CT can show not only the degree of HLH activity (including benign and malignant disease), but also the distribution of HLH in the whole body. However, PET/CT scans alone are not enough to make a correct differential diagnosis among different potential diseases. Biopsy is essential to definitively distinguish malignancy from infection. Further research with a larger population and multicenter data analysis should be undertaken to validate the clinical role of PET/CT in secondary HLH. 
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